Trexquant Investment’s Monte Rosa Therapeutics GLUE Stock Holding History

Trexquant Investment’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$809K	Sell	49,179 -100,533	-67%	-$1.92M	0.01%	1306
2025 Q4	$2.35M	Buy	+149,712	New	+$2.02M	0.02%	934
2025 Q2	–	Sell	-26,188	Closed	-$122K	–	1656
2025 Q1	$122K	Buy	+26,188	New	+$161K	﹤0.01%	1494
2023 Q4	–	Sell	-25,657	Closed	-$123K	–	1560
2023 Q3	$123K	Buy	25,657 +10,935	+74%	+$70.4K	﹤0.01%	1387
2023 Q2	$101K	Sell	14,722 -7,003	-32%	-$45.3K	﹤0.01%	1371
2023 Q1	$169K	Buy	21,725 +4,791	+28%	+$33.3K	﹤0.01%	1347
2022 Q4	$129K	Sell	16,934 -24,666	-59%	-$205K	﹤0.01%	1298
2022 Q3	$340K	Buy	+41,600	New	+$382K	0.01%	969

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Trexquant Investment's GLUE Position: Q1 2026 in Review

Trexquant Investment reduced its Monte Rosa Therapeutics (GLUE) stake by 67% in Q1 2026, selling an estimated $1.92M and leaving 49,179 shares worth $809K. The position accounts for 0.01% of the portfolio, ranked #1306.

Trexquant Investment first reported a position in GLUE in Q3 2022 and has held it in 8 quarters since. The position peaked at $2.35M in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

Trexquant Investment held 49,179 shares of Monte Rosa Therapeutics worth $809K as of Q1 2026.
Trexquant Investment sold 100,533 Monte Rosa Therapeutics shares in Q1 2026, an estimated $1.92M.
Monte Rosa Therapeutics made up 0.01% of Trexquant Investment's portfolio in Q1 2026, its #1306 holding.
Trexquant Investment first reported a position in Monte Rosa Therapeutics in Q3 2022 and has held it in 8 quarters since.
Trexquant Investment's Monte Rosa Therapeutics position peaked at $2.35M in Q4 2025.
190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.